药学学报, 2021, 56(2): 456-464
引用本文:
谢媛媛, 王义明, 罗国安. 生物标志物在药品生命周期中的应用与展望[J]. 药学学报, 2021, 56(2): 456-464.
XIE Yuan-yuan, WANG Yi-ming, LUO Guo-an. Identification and application of biomarkers in life cycle of drugs[J]. Acta Pharmaceutica Sinica, 2021, 56(2): 456-464.

生物标志物在药品生命周期中的应用与展望
谢媛媛1,3,4, 王义明2, 罗国安2
1. 广东药科大学中药学院, 广东 广州 510006;
2. 清华大学化学系, 北京 100084;
3. 国家中医药管理局中药数字化质量评价技术重点研究室, 广东 广州 510006;
4. 广东省中药质量工程技术研究中心, 广东 广州 510006
摘要:
生物标志物(biomarker)是一种能客观测量并评价正常生物过程、病理过程或对药物干预反应的指示物,可有效提高新药研究开发决策,指导候选药物早期临床试验,降低新药研发失败的风险,其在药品生命周期中的重要作用已引起业内普遍关注。欧美等国家和地区相继出台关于生物标志物研究开发和资格鉴定程序的指南,鼓励医药企业将生物标志物作为创新药物发现的工具,在药品上市后通过生物标志物监控其安全性和有效性。本文针对我国药品生命周期特点,对生物标志物在药物基础研究、先导化合物/创新药物的设计与发现、临床前药物开发、临床研究、新药研究及上市后再评价等药品生命周期各个环节中作用情况进行综述,并对其应用前景进行展望。
关键词:    生物标志物      药品生命周期      新药研发      有效性      安全性     
Identification and application of biomarkers in life cycle of drugs
XIE Yuan-yuan1,3,4, WANG Yi-ming2, LUO Guo-an2
1. School of Traditional Chinese Medicine, Guangdong Pharmaceutical University, Guangzhou 510006, China;
2. Department of Chemistry, Tsinghua University, Beijing 100084, China;
3. Key Laboratory of Digital Quality Evaluation of Chinese Material Medical of SATCM, Guangzhou 510006, China;
4. Engineering Technology Research Center for Chinese Materia Medical Quality of Guangdong Province, Guangzhou 510006, China
Abstract:
Biomarkers are defined as a characteristic that is objectively measured and evaluated as an indicator of normal biological processes, pathogenic processes, or pharmacological responses to a therapeutic intervention. Biomarkers can help the decision-making process for new drug research and development, provide guidance for the early clinical development of candidate drugs and reduce the risk of failure. Therefore, as a key factor in the development of new drugs, the discovery and research on biomarkers has increased the interest of the pharmaceutical industry and regulatory agencies. Guidelines on the development and use of biomarkers have been issued by drug regulatory agencies including the EMA, FDA and ICH. Biomarkers are encouraged to be used to facilitate drug development by these relevant regulatory agencies, and also to be used to monitor the safety and efficacy of drugs in post-marketing drug surveillance. The application of biomarkers is encouraged at different stages of a drug's life cycle, including at the stage of basic science research and target identification, prototype design or discovery, preclinical development, clinical development, FDA filling/approval and launch, as well as post-marketing was reviewed. The identification, development, and application of biomarkers in pharmaceutical research is discussed.
Key words:    biomarker    life cycle of drug    drug discovery    efficacy    safety   
收稿日期: 2020-08-19
DOI: 10.16438/j.0513-4870.2020-1374
基金项目: 国家自然科学基金重点基金资助项目(81130066);国家自然科学基金面上项目(81473174);国家药典委员会药品标准制修订研究课题(2019Y12).
通讯作者: 罗国安,Tel:86-10-62781688,E-mail:luoga@tsinghua.edu.cn
Email: luoga@tsinghua.edu.cn
相关功能
PDF(910KB) Free
打印本文
0
作者相关文章
谢媛媛  在本刊中的所有文章
王义明  在本刊中的所有文章
罗国安  在本刊中的所有文章

参考文献:
[1] ICH. Quality Management File Compilation (ICH质量管理文件汇编)[M]. Beijing:China Medical Science and Technology Press, 2010.
[2] Xie YY, Zhang T, He LC, et al. Application of biomarkers in life cycle of drugs and related regulations[J]. Drug Stand Chin (中国药品标准), 2020, 21:5-13.
[3] Wu JR. Three critical factors on drug research and development[J]. Science (科学), 2019, 71:27-29.
[4] Liu DD, Han L, Yu JP, et al. Research progress on biomarkers related to the efficacy and prognosis of tumor immunotherapy[J]. Chin J Cancer Biother (中国肿瘤生物治疗杂志), 2019, 26:1148-1155.
[5] Sandip SK, Vaishali RS, Manjusha N, et al. Review on biomarkers:tools for diagnosis of a disease and drug development[J]. Indo Am J Pharm Res, 2019, 9:3010-3019.
[6] Planchard D, Giroux LE. Biomarkers and targeted therapies in non-small cell lung cancer:present and future treatments[J]. Rev Pneumol Clin, 2011, 67:S36-S40.
[7] Khanal N, Ganti AK. Emerging targeted therapies in non-small cell lung cancer[J]. Expert Rev Anticancer Ther, 2016, 16:177-187.
[8] Krishna R, Herman G, Wagner JA. Accelerating drug development using biomarkers:a case study with sitagliptin, a novel DPP4 inhibitor for type 2 diabetes[J]. AAPS J, 2008, 10:401-409.
[9] Sheila ET, Gary MC, Janet ED, et al. A perspective on challenges and issues in biomarkers development and drug and biomarker codevelopment[J]. J Natl Cancer Inst, 2019, 101:1453-1463.
[10] Luo GA, Wang YM, Fang XM, et al. Research strategy and practice from clinical reality, targeting at signaling pathways for the innovative compound drug——the sixth discussion on the proposal of holistic systems medicine[J]. World Sci Technol Mod Tradit Chin Med Mater Med (世界科学技术-中医药现代化), 2018, 20:1047-1068.
[11] Luo GA, Lian QL, Liu QF, et al. Prospect on the composite drugs innovation system[J]. World Sci Technol Mod Tradit Chin Med Mater Med (世界科学技术-中医药现代化), 2009, 11:3-10.
[12] Ellen LB. Systems biology in drug discovery and development[J]. Drug Discov Today, 2014, 19:113-125.
[13] Brijesh SY, Vijay T. Recent advances in the system biology-based target identification and drug discovery[J]. Curr Top Med Chem, 2018, 18:1737-1744.
[14] Tan XQ, Xiong JC, Zhu TF, et al. Development of drug design in China:40 years of achievements[J]. Sci Sin Vitae (中国科学:生命科学), 2019, 49:1375-1394.
[15] Jiang Y, Li J, Tu PF. Research approaches on discovery R&D of innovative drug of chinese materia medica under new situations[J]. World Sci Technol Mod Tradit Chin Med Mater Med (世界科学技术-中医药现代化), 2017, 19:892-899.
[16] Li YG, Li Y, Cui LL, et al. Modern application and thinking of traditional Chinese medicine disease and syndrome combined with animal model[J]. Chin Tradit Herb Drugs (中草药), 2019, 50:3971-3978.
[17] Li SH, Li SN, Zhou F, et al. Thought on study of animal models of traditional Chinese medicine syndromes[J]. Chin J Tradit Chin Med Pharm (中华中医药杂志), 2019, 34:3357-3361.
[18] Huang ZQ, Fan XM, Wang YM, et al. A new method to evaluate the dose-effect relationship of a TCM formula Gegen Qinlian decoction:"focus" mode of integrated biomarkers[J]. Acta Pharmacol Sin, 2017, 38:1141-1149.
[19] Luo GA, Xie YY, Wang YM, et al. Precision medicine and modernization research on traditional Chinese medicine——the fifth discussion on the proposal of holistic systems medicine[J]. World Sci Technol Mod Tradit Chin Med Mater Med (世界科学技术-中医药现代化), 2017, 19:19-29.
[20] Zhou YY, Zhao HY, Wang HJ, et al. The correlation between of "Shanghuo" (upper fever) and biomarkers[J]. J Zhejiang Chin Med Univ (浙江中医药大学学报), 2019, 43:97-102, 110.
[21] Emens LA. Breast cancer immunotherapy:facts and hopes[J]. Clin Cancer Res, 2018, 24:511-520.
[22] Patel SP, Kurzrock R. PD-L1 expression as a predictive biomarker in cancer immunotherapy[J]. Mol Cancer Ther, 2015, 14:847-856.
[23] Jiang YB, Lo AWI, Wong A, et al. Prognostic significance of tumor-infiltrating immune cells and PD-L1 expression in esophageal squamous cell carcinoma[J]. Oncotarget, 2017, 8:30175-30189.
[24] Chen HJ, Wang SQ. Breast cancer immunotherapy:biomarkers, drugs and vaccines[J]. Chin J Biochem Mol Biol (中国生物化学与分子生物学报), 2019, 35:1080-1085.
[25] Goodsaid F. The Path from Biomarker Discovery to Regulatory Qualification (生物标志物:从研发到审评鉴定之路径)[M]. Beijing:Science Press, 2016.
[26] Luo GA, Wang YM. Exploration on Holistic Systemic Medicine (整体系统医药学探索)[M]. Beijing:Science Press, 2020.
[27] Kewal KJ. The Handbook of Biomarkers (生物标志物手册)[M]. Beijing:Chemical Industry Press, 2015.
[28] Lin Z, Zhou XB, Lv JJ, et al. Research progress on biomarker validation in drug safety evaluation[J]. Drug Eval Res (药物评价研究), 2016, 39:1070-1074.
[29] Dieterle F, Sistare F, Goodsaid F, et al. Renal biomarkers qualification submission:a dialog between the FDA-EMEA and predictive safety testing consortium[J]. Nat Biotechnol, 2010, 28:455-462.
[30] Dieterle F, Perentes E, Cordier A, et al. Urinary clusterin, cystatin C, β2-microglobulin and total protein as markers to detect drug-induced kidney injury[J]. Nat Biotechnol, 2010, 28:463-469.
[31] Ennulat D, Adler S. Recent successes in the identification, development, and qualification of translational biomarkers:the next generation of kidney injury biomarkers[J]. Toxicol Pathol, 2015, 43:62-69.
[32] Fuchs TC, Hewitt P. Biomarkers for drug-induced renal damage and nephrotoxity:an overview for applied toxicology[J]. AAPS J, 2011, 13:615-631.
[33] Newby LK, Rodriguez I, Finkle J, et al. Troponin measurements during drug development-considerations for monitoring and management of potential cardiotoxicity:an educational collaboration among the Cardiac Safety Research Consortium, the Duke Clinical Research Institute, and the US Food and Drug Administration[J]. Am Heart J, 2011, 162:64-73.
[34] Thomas LJ, Bell D, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib[J]. N Engl J Med, 2004, 350:2129-2139.
[35] Lavertu A, Mcinnes G, Daneshjou R, et al. Pharmacogenomics and big genomic data:from lab to clinic and back again[J]. Hum Mol Genet, 2018, 27:R72-R78.
[36] Henderson LM, Robinson RF, RAY L, et al. VKORC1 and Novel CYP2C9 variation predict warfarin response in Alaska native and American Indian people[J]. Clin Transl Sci, 2019, 12:312-320.
[37] Vazquez SR. Drug-drug interactions in an era of multiple anticoagulants:a focus on clinically relevant drug interactions[J]. Blood, 2018, 132:2230-2239.
[38] Benincasa G, Costa D, Infante T, et al. Interplay between genetics and epigenetics in modulating the risk of venous thromboembolism:a new challenge for personalized therapy[J]. Thromb Res, 2019, 177:145-153.
[39] Xiong ZP, Zhu P, Huang SQ, et al. Research progress on pharmacogenetics in multidrug and toxin extrusion proteins[J]. Chin Pharmacol Bull (中国药理学通报), 2016, 32:1639-1643.
[40] Ebert MP, Tanzer M, Balluff B, et al. TFAP2E-DKK4 and chemoresistance in colorectal cancer[J]. N Engl J Med, 2012, 366:44-53.
[41] Cooper GM, Johnson JA, Langaee TY, et al. A genome-wide scan for common genetic variants with a large influence on warfarin maintenance dose[J]. Blood, 2008, 112:1022-1027.
[42] Iorio F, Knijnenburg TA, Vis DJ, et al. A landscape of pharmacogenomic interactions in cancer[J]. Cell, 2016, 166:740-754.
[43] Goldstein RL, Yang SN, Taldone T, et al. Pharmacoproteomics identifies combinatorial therapy targets for diffuse large B cell lymphoma[J]. J Clin Invest, 2015, 125:4559-4571.
[44] Miolo G, Muraro E, Crivellari D, et al. Pharmacometabolomics study identifies circulating spermidine and tryptophan as potential biomarkers associated with the complete pathological response to trastuzumab-paclitaxel neoadjuvant therapy in HER-2 positive breast cancer[J]. Oncotarget, 2016, 7:39809-39822.
[45] Zhang TJ, Bai G, Liu CX. The concept, core theory and research methods of Chinese medicine quality markers[J]. Acta Pharm Sin (药学学报), 2019, 54:187-196.
[46] Li XJ, Huang YY, Yang Z, et al. Research strategy for quality-biomarkers of traditional Chinese medicine based on effect benchmarks[J]. Acta Pharm Sin (药学学报), 2019, 54:204-210.
相关文献:
1.张晓东, 成龙, 李耿, 孙晓波.从FDA《植物药指南》(修订稿)探讨临床研究的重点与难点[J]. 药学学报, 2017,52(4): 505-509